Fierce Pharma

APRIL 18, 2023

Embracing Personalization in Biopharma Patient Support Programs mteefey Tue, 04/18/2023 - 14:48

Biopharma 246

Biopharma Patients 246

Fierce Pharma

MAY 16, 2023

FTC seeks to block Amgen's $28B Horizon buy in 'broadly negative' move for biopharma M&A: report aliu Tue, 05/16/2023 - 09:41

Biopharma 299

Biopharma 299

Fierce Pharma

SEPTEMBER 7, 2023

Biopharma M&A is on an uptick compared to the post-pandemic doldrums of the last two years. Biopharma M&A is on an uptick compared to the post-pandemic doldrums of the last two years. Analysts anticipate that the trend will continue in 2023 and into 2024 as companies attempt to beef up their portfolios.

Biopharma 338

Biopharma Pharma 338

Fierce Pharma

MARCH 21, 2023

Biopharma industry lobbies for tax breaks related to US-based manufacturing kdunleavy Tue, 03/21/2023 - 11:14

Biopharma 264

Biopharma Manufacturing 264

Fierce Pharma

MAY 16, 2024

The momentum the biopharma industry showed in the fourth quarter of 2023 has continued into this year. | The momentum the biopharma industry showed in the fourth quarter of 2023 has continued into this year.

Biopharma 312

Biopharma Pharma 312

Fierce Pharma

DECEMBER 21, 2022

Tamiflu generics in short supply in latest chapter of biopharma's shortage saga. fkansteiner. Wed, 12/21/2022 - 08:40.

Biopharma 268

Biopharma 268

Fierce Pharma

JANUARY 8, 2024

Biopharma companies looking to maximize the visibility of their M&A activity often reveal deals during the J.P. In it’s annual Firepower report, EY says the biopharma industry enters 2024 with the capability and motivation to increase M&A activity. Morgan Healthcare Conference. |

Prospecting 302

Prospecting Biopharma Pharma Healthcare 302

Fierce Pharma

JUNE 14, 2023

billion buyout of Horizon Therapeutics has raised concerns that the United States’ antitrust watchdog is tightening the screws on major M&A moves in the biopharma industry. An FTC lawsuit aimed at blocking Amgen’s $27.8 billion buyout o | An FTC lawsuit aimed at blocking Amgen’s $27.8

Biopharma 299

Biopharma 299

Fierce Pharma

FEBRUARY 29, 2024

Venture capital firms pitching in on drug development isn’t exactly a new way of doing business for the biopharma industry. Venture capital firms pitching in on drug development isn’t exactly a new way of doing business for the biopharma industry.

Biopharma 298

Biopharma Pharma 298

Fierce Pharma

JANUARY 16, 2024

A USA Today review of millions of Glassdoor ratings found that employees in the biopharma industry are the most satisfied with their pay compared with other fields. 2023 was riddled with labor strikes across industries as workers lobbied for higher pay amid economic headwinds that shook up the global economy. |

Biopharma 264

Biopharma 264

Fierce Pharma

SEPTEMBER 14, 2023

Amid the Federal Trade Commission's (FTC's) campaign to bolster scrutiny around large biopharma M&A deals, the agency is now taking a closer look at patent gamesmanship. |

Biopharma 275

Biopharma Pharmaceutical 275

Fierce Pharma

AUGUST 27, 2024

An expert recently discussed the ramifications of the ruling during a Fierce Pharma podcast interview. . | In June, when the Supreme Court voted 6-3 to overturn the Chevron doctrine, it brought significant impact for the healthcare industry and federal regulators like the FDA and the Centers for Medicare & Medicaid Services.

Biopharma 312

Biopharma FDA Pharma Healthcare 312

Fierce Pharma

AUGUST 21, 2024

A survey of 800 biopharma executives shows that sustainability is an increasingly important priority but that companies are struggling to achieve it.

Biopharma 299

Biopharma Pharma 299

Fierce Pharma

OCTOBER 3, 2024

On the same day as Roche's Pharma Day in London, the biopharma giant revealed a high-dollar deal with Chinese-American biotech Regor for the latter's CDK inhibitors. |

Pharma 246

Pharma Biopharma Sales 246

Fierce Pharma

DECEMBER 20, 2022

2023 forecast: An 'inflection point' for biopharma, fueled by a flood of AI and machine learning products. Tue, 12/20/2022 - 13:39.

Biopharma 264

Biopharma 264

Fierce Pharma

APRIL 11, 2024

As lawmakers, biopharma companies and others try to stabilize vulnerable pharma supply chains, drug shortages have become about as bad as they’ve ever been in the U.S. | The American Society of Health-System Pharmacists has released new data showing there were 323 drugs in shortage in the U.S.

Biopharma 328

Biopharma Pharma 328

Fierce Pharma

MAY 25, 2023

The Top Line': The 20 most influential people in biopharma, plus this week's headlines tcarey Thu, 05/25/2023 - 14:21

Biopharma 244

Biopharma 244

Fierce Pharma

APRIL 19, 2023

Alnylam, Intra-Cellular among analyst's top picks for M&A as biopharma dealmaking heats up aliu Wed, 04/19/2023 - 14:39

Biopharma 245

Biopharma 245

Fierce Pharma

MAY 9, 2023

Let's make a deal: Conditions are right for biopharma M&A to break out, analysts say kdunleavy Tue, 05/09/2023 - 10:18

Biopharma 246

Biopharma 246

Fierce Pharma

NOVEMBER 27, 2023

It was the second straight quarter where the overwhelming success of blood sugar regulating treatments were the dominant story in the biopharma industry. Eli Lilly’s fortunes have turned quickly. | Eli Lilly and Novo Nordisk delivered the highest revenue gains, at 38% and 29%, respectively.

Biopharma 306

Biopharma Pharma 306

Fierce Pharma

DECEMBER 2, 2024

Department of Health and Human Services immediately sent waves of speculation swirling throughout the biopharma industry. | Kennedy Jr.’s s appointment last month to lead the U.S. The former FDA Commissioner pointed to the threat of measles if vaccination rates were to decline by 5%.

Biopharma 363

Biopharma FDA Leads 363

Fierce Pharma

SEPTEMBER 25, 2023

A who’s who of biopharma companies have backed a push to rai | A who’s who of biopharma companies have backed a push to raise awareness about lung cancer among Hispanic and Latino Americans, funding a project that has enlisted a Mission: Impossible star to educate the community about risk factors, early warning signs and screening.

Biopharma 244

Biopharma Education Pharma 244

Fierce Pharma

MAY 1, 2024

Just about two months into his CEO job at Emergent BioSolutions, Joseph Papa has laid out his turnaround plan for the CDMO-turned-biopharma company. Merely about two months into his CEO job at Emergent BioSolutions, Joseph Papa has laid out his turnaround plan for the CDMO-turned-biopharma company.

Biopharma 343

Biopharma 343

Fierce Pharma

MARCH 11, 2024

The decades-long wait for an effective treatment for metabolic dysfunction-associated steatohepatitis (MASH) has ended, as the FDA has approved the first drug for the fatty liver disease. | The decades-long wait for an effective treatment for metabolic dysfunction-associated steatohepatitis (MASH) has ended.

FDA 350

FDA Biopharma 350

Fierce Pharma

MAY 10, 2024

Right after an industry survey suggested that switching away from Chinese CDMOs could take biopharma companies up to eight years, lawmakers have adjusted the BIOSECURE Act. The new draft lays out a 2032 deadline for the separation mandate.

Biopharma 345

Biopharma 345

Fierce Pharma

DECEMBER 22, 2023

Even with the Federal Trade Commission keeping a watchful eye on the biopharma industry and the economic landscape giving some players pause, mergers and acquisitions are back on the rise.

Biopharma 350

Biopharma 350

Fierce Pharma

NOVEMBER 22, 2024

With a 32% revenue increase, Pfizer jumped into the top spot.

Biopharma 307

Biopharma Sales 307

Fierce Pharma

AUGUST 20, 2024

As House lawmakers prepare for a September vote on the controversial BIOSECURE Act, the House Select Committee on the CCP is expanding the scope of its scrutiny on China's biopharma ecosystem. |

Biopharma 338

Biopharma FDA 338

Fierce Pharma

JUNE 6, 2024

More Chinese biopharma players are coming under scrutiny from U.S. . | AstraZeneca and Daiichi Sankyo are looking at moving their antibody-drug conjugate Enhertu into another new breast cancer patient class. Ahead of the American Society of Clinical Oncology annual meeting, a cancer antibody from Akeso and Summit Therapeutics stole the show.

Biopharma 244

Biopharma Pharma Patients 244

Fierce Pharma

AUGUST 15, 2023

As the coronavirus surged and subsided, several biopharma companies experienced exaggerated revenue spikes and troughs. Thanks to sales of their metabolism drugs, Novo Nordisk and Eli Lilly posted the biopharma industry’s largest revenue gains in the second quarter—by far.

Biopharma 246

Biopharma Sales Pharma 246

Fierce Pharma

FEBRUARY 21, 2024

In a year that started with more than two-thirds of biopharma companies posting | While Novo Nordisk and Eli Lilly continued to be the biopharma industry growth leaders in the fourth quarter of 2023, many other drugmakers also delivered big gains, including Daiichi Sankyo, Amgen, Teva, GSK and Novartis.

Leads 312

Leads Biopharma Sales 312

Fierce Pharma

JUNE 6, 2023

Novo Holdings and Gurnet Point have added antibiotics maker Paratek Pharma to their fold in a biopharma M&A deal worth approximately $462 million. Paratek's key selling point is its antibiotic, Nuzyra, which was expected to garner $500 million in peak sales at the time of its 2018 approval.

Biopharma 264

Biopharma Sales Pharma 264

Fierce Pharma

JUNE 4, 2024

security crackdown on biopharma firms suspected to be linked to the Chinese Communist Party (CCP) has continued to gain steam. | security crackdown on biopharma firms suspected to be linked to the Chinese Communist Party has continued to gain steam. For several months, a U.S. For several months, a U.S.

Biopharma 306

Biopharma 306

Fierce Pharma

JANUARY 3, 2024

Booming demand for blood sugar-modulating diabetes and obesity drugs became the top trend in the biopharma industry in 2023, with two companies—Novo Nordisk and Eli Lilly—overwhelming the market wi | Booming demand for blood sugar-modulating diabetes and obesity drugs became the top trend in the biopharma industry in 2023, with two companies—Novo Nordisk (..)

Sales 321

Sales Biopharma Leads Marketing 321

Fierce Pharma

FEBRUARY 13, 2024

After introducing legislation targeting certain Chinese biopharma companies, a group of bipartisan lawmakers are taking their concerns to the White House—and upping the stakes.

Biopharma 311

Biopharma 311

Fierce Pharma

JULY 18, 2024

As biopharma companies and the U.S. | As biopharma companies and the U.S. government near the deadline of their drug price talks under the Inflation Reduction Act, Novartis CEO said the cost cuts “might be manageable” in the short term for the firm’s first few products to be included.

Management 296

Management Biopharma Government 296

Fierce Pharma

NOVEMBER 30, 2023

we're highlighting two weeks' worth of biopharma news related to Asia. Because of the recent Thanksgiving holiday in the U.S., AstraZeneca in-licensed a KRAS G12D inhibitor from China's Usynova. BeiGene bought global rights to a CDK2 inhibitor in a deal worth up to $1.3 market at a 20% discount to Merck's Keytruda.

Biopharma 246

Biopharma Pharma Marketing 246